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Hepatitis C virus screening was conducted among 
8,226 residents 25–65 years of age in 4 counties of China; 
virus prevalence was 0.9%. A subsequent case–control 
study indicated blood transfusion (odds ratio [OR] 4.55), 
esophageal balloon examination (OR 3.78), and intrave-
nous injection (OR 5.83) were associated with infection. 
H
epatitis C virus (HCV) infection shows clear differenc-
es in prevalence among geographic regions, according 
to World Health Organization data (1). HCV prevalence also 
varies over time and with behavioral changes (2,3). HCV 
prevalence in the People’s Republic of China nationwide 
was estimated at 3.2% in a 1992 survey (4), but studies have 
reported regional prevalence rates ranging from 0% to 31.9% 
(5–7). In developing countries, transmission of HCV typi-
cally results primarily from iatrogenic factors, such as blood 
transfusion and inadequate sterilization or reuse of medical 
equipment (8), but in industrialized countries, risk resulting 
from these factors has been greatly reduced (9,10).
In an esophageal endoscopic survey (2006–2008) in 
Anyang, Henan Province, China, blood screening for the 
HCV antibody was carried out in all participants. Because 
HCV infection is an important public health issue, a case–
control study was performed among HCV-positive case-
patients with matched controls to evaluate risk factors for 
HCV infection in the area where the esophageal endoscopic 
survey was conducted.
The Study
An endoscopic survey (2006–2008) for esophageal 
cancer was conducted in 8 villages of 4 counties of Anyang, 
Henan Province, China (Figure). The villages were selected 
on the basis of population size, location, and village admin-
istrative capabilities. A total of 10,240 permanent residents 
were eligible for the survey; 8,226 (80.3%) persons 25–65 
years of age (median age 42.0, M:F sex ratio 1.00:1.18) 
without cardiovascular or psychological diseases were in-
terviewed and had blood drawn. A total of 74 participants 
were seropositive for HCV in this screening; 69 of them 
were enrolled in the subsequent case–control study. Each 
seropositive person was matched with 3 negative controls 
randomly selected from seronegative participants (2.5%) 
of the same village, gender, and age (±2 years). A ques-
tionnaire regarding lifetime risk factors for HCV infection 
was given to HCV seropositive case-patients and matched 
controls. The Institutional Review Board of the School of 
Oncology, Peking University, China, approved this study. 
Informed consent was obtained from all participants.
Serum samples were separated from blood samples by 
centrifugation and tested for HCV in the Anyang Cancer 
Hospital for case-patients from Anyang, Lin, and Tangyin 
counties, and in the Hua County Hospital for case-patients 
from Hua County. ELISAs were performed to evaluate for 
HCV antibody (Diagnostic Kit for HCV ELISA 3.0; Auto-
Bio Co., Zhengzhou, China). HCV-positive case-patients 
submitted an additional blood sample for a conﬁ  rmatory 
HCV test in Anyang Cancer Hospital. Positivity for HCV 
antibody in these 2 tests was independently conﬁ  rmed at 
Beijing Friendship Hospital by ELISA (Diagnostic Kit 
HCV 3.0; Abbott GmbH & Co. KG, Wiesbaden-Delken-
heim, Germany). We determined the positive predictive 
value of the anti-HCV tests conducted in China to be 98.3% 
by using the testing result of the Abbott diagnostic kit as a 
standard. Assays were monitored with internal and external 
quality controls.
We examined group differences using the χ2 test. Uni-
variate and multivariate conditional logistic regression 
were used to identify signiﬁ  cant factors for HCV infection. 
Data entry and statistical analysis were conducted using 
Epi Data 3.1 (www.cdc.gov/epiinfo) and SAS 9.1.3 (SAS, 
Cary, NC, USA); p<0.05 was considered signiﬁ  cant.
Seventy-four (0.9%) of 8,266 participants were HCV 
positive. Prevalence of infection varied signiﬁ  cantly with 
age (p<0.001) and county of origin (p<0.001) but not with 
gender (Table 1). HCV prevalence was signiﬁ  cantly higher 
in participants >50 years of age. Prevalence was highest in 
Lin County (2.8%), followed by Anyang County (0.7%), 
Tangyin County (0.4%), and Hua County (0.2%) (Table 1). 
The Lin County >50-year-old group showed an 18.25-fold 
higher risk for HCV infection (95% conﬁ  dence interval 
[CI] 9.29–35.83) when compared with non–Lin County 
participants <50 years of age (data not shown).
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 11, November 2009  1819 
1These authors contributed equally to this article.
Author afﬁ  liations: Ministry of Education Key Laboratory, Beijing, 
People’s Republic of China (F. Liu, K. Chen, T. Ning, Y. Pan, H. 
Cai, Y. Ke); Peking University School of Oncology, Beijing (F. Liu, 
K. Chen, T. Ning, Y. Pan, H. Cai, Y. Ke); Beijing Cancer Hospital 
and Institute, Beijing (F. Liu, K. Chen, T. Ning, Y. Pan, H. Cai, 
Y. Ke); and Peking University School of Public Health, Beijing 
(Z. He)
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evaluate possible risk factors based on information collect-
ed from the 69 HCV-positive participants and 207 matched 
controls. Transfusion with blood and blood products, in-
travenous injection, and procedures including Caesarean 
section, acupuncture, gastroscopy, and esophageal balloon 
examination were associated with higher risk for HCV 
infection. No instances of hemodialysis, organ transplan-
tation, drug use, or homosexual behavior were identiﬁ  ed. 
However, when these risk factors were analyzed in a mul-
tivariate model, only blood transfusion (odds ratio [OR] 
4.55, 95% CI 1.34–15.42), intravenous injection (OR 5.83, 
95% CI 2.66–12.80), and esophageal balloon examination 
(OR 3.78, 95% CI 1.32–10.79) were signiﬁ  cant (Table 2). 
A repeat analysis of participants from Lin County produced 
almost identical results (data not shown).
Conclusions
In this 2006–2008 study, overall HCV prevalence was 
0.9%, with prevalence highest in the >50-year-old group of 
Lin County (4.7%). In a 2000 study of 55- to 84-year-old 
Lin County residents, the prevalence of HCV was 9.6% (7). 
Several possible reasons could explain these differences. 
One is that the average age in the previous study (range 
64–84 years) was greater than that in our study (range 25–
65 years); older persons were more likely to be infected in 
both the previous study and our study. The time interval 
between these 2 studies might also have contributed to the 
change in HCV prevalence.
A case–control study was performed to identify HCV 
infection risk factors. Blood transfusion and medical intra-
venous injection with reusable glass syringes and needles, 
which are established HCV risk factors, were associated 
with HCV infection (10,11). In addition, esophageal bal-
loon examination, a less commonly identiﬁ   ed route of 
HCV infection, also increased the risk for HCV infection. 
In the recent past (1980–2000), esophageal balloon exami-
nation, which was designed for early cytologic detection 
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Figure. A) Map of eastern China showing the location of Anyang 
(red dot). B) Villages (red dots) targeted in the 2006–2008 hepatitis 
C virus prevalence study.
Table 1. Demographic distribution and HCV infection status of 
participants (n = 8,226) in an esophageal endoscopic survey for 
HCV, Anyang, China, 2006–2008* 
Variable Total no. (%)  HCV-positive, no. (%) p value 
Age, y 
<50 5,766 (70.1)  37 (0.6)  <0.001
 >50 2,460 (29.9)  37 (1.5) 
Sex 
  M  3,782 (46.0)  31 (0.8)  0.479
  F  4,444 (54.0)  43 (1.0) 
County 
  Hua  4,022 (48.9)  7 (0.2)  <0.001
  Anyang  838 (10.2)  6 (0.7) 
  Lin  1,980 (24.1)  55 (2.8) 
  Tangyin  1,386 (16.8)  6 (0.4) 
*HCV, hepatitis C virus. Hepatitis C, Anyang, China
of esophageal lesions, was relatively common in China for 
diagnosis and screening of persons in high-risk popula-
tions (12). In this technique, the patient swallows a balloon 
covered with a cotton net. The balloon is inﬂ  ated within 
the patient’s stomach. Exfoliated esophageal cells are then 
scraped off the mucosa by pulling out the balloon. Bleed-
ing of esophageal mucosa can occur. The balloon and cot-
ton net were designed to be nonreusable. Nonetheless, on 
some occasions, balloons were reused after manual clean-
ing. This technique is no longer widely used; however, Lin 
County is a high-risk area for esophageal cancer. Screening 
for esophageal cancer using balloon examination was per-
formed in this region before 2000. Reuse of balloons and 
occasional bleeding during the procedure may have caused 
transmission of HCV in this population.
A nationwide survey for HCV infection in China was 
performed in 1992; prevalence was 3.1% for residents in 
rural areas. However, prevalence of viral infection was 
not consistent across regional populations, similar to what 
was observed in the present study (4). On the basis of these 
regional differences in HCV distribution and the potential 
risk factors identiﬁ  ed in this study, we strongly suggest that 
unregulated medical procedures may confer substantial 
risk for HCV spread.
Chronic infection will develop in ≈75%–85% of per-
sons infected with HCV, and cirrhosis of the liver will de-
velop in up to 20% of chronically infected persons. Hepa-
tocellular carcinoma will develop in ≈3%–4% of patients 
with HCV-associated cirrhosis each year (13–15). Given 
the serious social and economic effect of this HCV epi-
demic, strengthening administrative regulation of medical 
practice, especially in rural areas, and providing appro-
priate education to the public about HCV infection and 
its transmission should be given higher priority in public 
health policy. 
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Table 2. Conditional logistic analysis of risk factors associated with hepatitis C virus infection, Anyang, China, 2006–2008* 
Risk factor†  Response Total no. 
HCV negative, 
no. (%) 
HCV positive, 
no. (%)  OR (95% CI)  Adjusted OR (95% CI) 
No 258 195 (94.2)  63 (91.3)  1 Alcohol consumption 
Yes  18 12 (5.8)  6 (8.7)  1.71 (0.54–5.39) 
No 261 199 (96.1)  62 (89.9)  1 Blood donation 
Yes  15 8 (3.9)  7 (10.1)  3 (0.99–9.09) 
No 248 197 (95.2)  51 (73.9)  1 1 Blood transfusion 
Yes  28 10 (4.8)  18 (26.1)  6.32‡ (2.73–14.6)  4.55§ (1.34–15.42) 
No 249 191 (92.3)  58 (84.1)  1 1 Blood products transfusion 
Yes  27 16 (7.7)  11 (15.9)  2.49§ (1.03–6.05)  0.99 (0.28–3.5) 
No 39 32 (15.5)  7 (10.1)  1 Intramuscular injection 
Yes  237 175 (84.5)  62 (89.9)  1.77 (0.69–4.59) 
No 153 136 (65.7)  17 (24.6)  1 1 Intravenous injection 
Yes  123 71 (34.3)  52 (75.4)  6.75‡ (3.41–13.36)  5.83‡ (2.66–12.8) 
No 136 103 (49.8)  33 (47.8)  1 Visited a dentist 
Yes  140 104 (50.2)  36 (52.2)  1.09 (0.62–1.9) 
No 210 171 (82.6)  39 (56.5)  1 1 Had surgery 
Yes  66 36 (17.4)  30 (43.5)  3.78‡ (2.01–7.1)  2.29 (0.92–5.71) 
No 66 51 (24.6)  15 (21.7)  1 Shared nail clippers 
Yes  210 156 (75.4)  54 (78.3)  1.17 (0.62–2.23) 
1 262 194 (93.7)  68 (98.6)  1 No. sexual partners 
>1 14 13 (6.3)  1 (1.4)  0.21 (0.03–1.66) 
No 173 129 (62.3)  44 (63.8)  1 Pierced ears 
Yes  103 78 (37.7)  25 (36.2)  0.88 (0.4–1.96) 
No 215 168 (81.2)  47 (68.1)  1 Acupuncture
Yes  61 39 (18.8)  22 (31.9)  2.15§ (1.11–4.13)  1.61 (0.69–3.76) 
No 246 190 (91.8)  56 (81.2)  1 Gastroscopy 
Yes  30 17 (8.2)  13 (18.8)  2.92§ (1.27–6.72)  2.06 (0.63–6.7) 
No 240 190 (91.8)  50 (72.5)  1 Esophageal balloon 
examination Yes  36 17 (8.2)  19 (27.5)  5.95‡ (2.44–14.5)  3.78§ (1.32–10.79) 
*HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval. 
†Blood transfusion, blood products transfusion, intravenous injection, operation, acupuncture, gastroscopy, and esophageal balloon examination were 
included in the multivariate model.  
‡p<0.01. 
§p<0.05. istry of Science and Technology Grants 2006AA2Z467 and 
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